Company news

Share this article:
AstraZeneca posted a third quarter sales increase of 3%, to 7.8 billion, according to a company report released today. Emerging markets contributed $1.1 billion – an 18% growth – to the bottom line. In China specifically, the company saw a 35% increase in sales. Crestor profited from its atherosclerosis indication, and US sales of the drug increased by 23%, marking the only branded statin to gain market share in the US this year, according to a company statement. “AstraZeneca has delivered a robust set of results that deliver on our performance commitments despite an increasingly challenging environment for the pharmaceutical sector and business in general,” said David Brennan, CEO, in the report.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.